Current treatment strategies for multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue SUPPL. 4, 2007, Pages

  Thomas, Sheeba ^a   Alexanian, Raymond ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Proteasome inhibitors; Tandem transplantation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; FLUDARABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PREDNISONE; THALIDOMIDE; VALACICLOVIR; VASCULOTROPIN INHIBITOR; VINCRISTINE; WARFARIN;

ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG MEGADOSE; DRY SKIN; FATIGUE; FEVER; FLUID RETENTION; HERPES ZOSTER; HUMAN; INDIGESTION; INSOMNIA; MONOTHERAPY; MULTIPLE MYELOMA; MYALGIA; NEUROPATHY; PERIPHERAL NEUROPATHY; PROGNOSIS; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 34249781147     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.s.014     Document Type: Article

References (52)

1. Weber DM, Dimopoulos MA, Moulopoulos LA, et al. Prognostic features of asymptomatic multiple myeloma. Brit J Haematol 1997; 97:810-814.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-757.
3. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose thetapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-1123.
4. Drayson M, Tang L, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with non-secretory multiple myeloma. Blood 2001; 97:2900-2902.
5. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
6. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431-436.
7. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584-593.
8. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867-4874.
9. Chen CI, White D, Kouroukis CT, et al. Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with pteviously untreated or treated Waldenstrom's macroglobulinemia (WM). Blood 2004; 104:896a (Abstract #3278).
10. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:667-675.
11. Richardson PG, Sonneveld R Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
12. Jagannath S, Durie BG, Wolf, J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
13. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
14. Popat R, Oakervee H, Curry N, et al. Reduced dose PAD combination therapy (PS-341/ bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005; 106:717a (Abstract #2554).
15. Wang LM, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Haematology. In press.
16. Mateos MV, Hernández JM, Hernández MT. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108:2165-2172.
17. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-3464.
18. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). J Clin Oncol 2006; 24(18 suppl):427s (Abstract #7521).
19. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (rev/dex) for newly diagnosed myeloma. Blood 2005; 106:4050-4053.
20. Knighr R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354:2079-2080.
21. Zangari M, Barlogie B, Jacobson J, et al. VTD regimen comprising velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003; 102:236a (Abstract #830).
22. Wang LM, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005; 106:231a (Abstract #784).
23. Richardson P, Schlossman R, Munshi N, et al. A phase 1 trial of lenalidomide (Revlimid®) with bortezomib (Velcade®) in relapsed and refractory multiple myeloma. Blood 2005; 106:110a (Abstract #365).
24. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 367:825-831.
25. Facon T, Mary JY, Hulin C, et al. Major superiority of melphalan - prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 2005; 106:230a (Abstract #780).
26. Dimopoulos MA, Pouli A, Zervas K. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14:1039-1044.
27. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105:127-130.
28. Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006; 106:848-858.
29. Cavo M, Zamagni E, Tosi P. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-39.
30. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-97.
31. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
32. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27:1037-1043.
33. Wang M, Delasalle K, Thomas S, et al. Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006; 108:123a (Abstract #403).
34. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502.
35. Sonneveld P, van der Holt B, Vellenga E, et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 trial. Blood 2005; 106:715a (Abstract #2545).
36. Hunter HM, Peggs K, Powles R, et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005; 128:496-502.
37. Giralt S, Aleman A, Anagnostopoulos A, et al. Fludatabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30:367-373.
38. Alexanian R, Weber D, Dimopoulos M, et al. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol 2000; 65:204-209.
39. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6:467-476.
40. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 108:3289-3294.
41. Stewart AK, Chen CI, Howson-Jan K. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10:8170-8176.
42. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24:937-944.
43. Richardson P, Schlossman R, Munshi N, et al. A phase I trial of lenalidomide (Revlimid®) with bortezomib (Velcade®) in relapsed and refractory multiple myeloma. Blood 2005; 106:110a (Abstract #365).
44. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II UARK 2001-37 - superior outcome in patients with normal cytogenetics and no prior T. Blood 2005; 106:717a (Abstract #2552).
45. Weber D, Chen C, Niesvizky R, et al. A multicenter, randomized, parallel-Group, double-blind, placebo-controlled study of lenalidomide plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. The 10th International Myeloma Workshop; April 10-14, 2005; Sydney, Australia. Abstract #738.
46. Wang M, Knight R, Dimopoulos M, et al. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received thalidomide in relapsed or refractory multiple myeloma (MM). J Clin Oncol 2006; 24(18 suppl):427s (Abstract #7522).
47. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98:428-435.
48. Ogata A, Chauhan D, Teoh G, et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159:2212-2221.
49. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003; 46:5097-5116.
50. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45:495-528.
51. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005; 25:2873-2884.
52. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63:4460-4471.